Pro Bono - 60 CT

Pro Bono - 60 CT by Ortho Molecular Products

Pro Bono - 60 CT is a joint health supplement designed to promote mineral density in your bone joints.* The product contains a complex, clinically tested (as acclaimed by the producer) mix of nutrients that may increase your bone density and alleviate symptoms such as joint pain, muscle fatigue, or even low energy.*

Who May Take Pro Bono - 60 CT?

You may be interested in taking Pro Bono - 60 CT by Ortho Molecular Products if you:

• suffer from symptoms such as:
• joint pain*
• muscle fatigue*
• lack of energy*
• want to support your general bone joint health*
• suffer from weak, low-density bones*

The Potential Impact of Pro Bono - 60 CT on Your Body

Pro Bono - 60 CT may have the following effects on your muscle and bone joint health:

• increasing skeletal strength*
• supporting bone remodeling*
• improving nutrition for building healthy bone density*

Even though supplements support your health, they will never be a substitute for a healthy, balanced diet. Always check with your healthcare provider if you have doubts about a new supplement. For more information, book a FREE product consultation with our medical advisors.

Recommendation:
Ortho Molecular suggests taking 2 packets of Pro Bono per day, one AM packet in the morning and one PM packet in the evening or as recommended by your health care professional. For the maintenance dose, Ortho Molecular suggests taking 1 packet per day alternating one AM packet on odd days and one PM packet on even days or as recommended by your health care professional.

Serving Size: 2 packets 
Servings Per Container: 30

Amount Per AM Packet:
Vitamin A (as Betatene®
Natural Mixed Carotenoids, Palmitate) 2,000 IU
Vitamin C (as Ascorbic Acid USP) 333mg
Vitamin D3 (as Cholecalciferol) 500 IU
Vitamin E (as d-Alpha
Tocopherol Succinate USP) 25 IU
Vitamin K (2 packets provide
500 mcg K1 as Phytonadione, 
25 mcg K2 as Menaquinone-7 (MK-7)) 262.5 mcg
Thiamin (Vitamin B1)
(from Thiamine Hydrochloride USP) 25 mg
Riboflavin (Vitamin B2 USP) 15 mg
Niacin (as Niacin USP, 
Niacinamide USP) 15 mg
Vitamin B6 (as Pyridoxine
Hydrochloride USP) 25 mg
Folate
(as Quatrefolic® (6S)-5-Methyltetrahydrofolic 
acid glucosamine salt) 400 mcg
Vitamin B12 (as Methylcobalamin) 250 mcg
Biotin 150 mcg
Pantothenic Acid (asd-Calcium 
Pantothenate USP) 25 mg
Calcium (as Calcium
Hydroxyapatite, DimaCal® Dicalcium Malate) 0 mg
Phosphorus
(as Calcium Hydroxyapatite) 0 mg
Iodine (from Kelp) 75 mcg
Magnesium
(as DiMagnesium Malate, Magnesium Citrate 
USP, TRAACS® Magnesium Lysinate Glycinate Chelate) 267 mg
Zinc (as TRAACS®
Zinc Bisglycinate Chelate) 7.5 mg
Selenium (as Selenium
Glycinate Complex) 100 mcg
Copper (as TRAACS®
Copper Bisglycinate Chelate) 0.5 mg
Manganese (as TRAACS®
Manganese Bisglycinate Chelate) 2.5 mg
Chromium (as O-polynicotinate) 100 mcg
Molybdenum (as TRAACS®
Molybdenum Glycinate Chelate) 75 mcg
Strontium Citrate 1g 
Boron (as Bororganic Glycine) 2.5 mg

Amount Per PM Packet:
Vitamin A (as Betatene®
Natural Mixed Carotenoids, Palmitate) 2,000 IU
Vitamin C (as Ascorbic Acid USP) 167 mg
Vitamin D3 (as Cholecalciferol) 500 IU
Vitamin E (as d-Alpha
Tocopherol Succinate USP) 25 IU
Vitamin K (2 packets provide
500 mcg K1 as Phytonadione, 
25 mcg K2 as Menaquinone-7 (MK-7)) 262.5 mcg
Thiamin (Vitamin B1)
(from Thiamine Hydrochloride USP) 25 mg
Riboflavin (Vitamin B2 USP) 15 mg
Niacin (as Niacin USP, 
Niacinamide USP) 15 mg
Vitamin B6 (as Pyridoxine
Hydrochloride USP) 25 mg
Folate
(as Quatrefolic® (6S)-5-Methyltetrahydrofolic 
acid glucosamine salt) 400 mcg
Vitamin B12 (as Methylcobalamin) 250 mcg
Biotin 150 mcg
Pantothenic Acid (asd-Calcium 
Pantothenate USP) 25 mg
Calcium (as CalciumHydroxyapatite, DimaCal® Dicalcium Malate) 1,000 mg
Phosphorus
(as Calcium Hydroxyapatite) 360 mg
Iodine (from Kelp) 75 mcg
Magnesium
(as DiMagnesium Malate, Magnesium Citrate 
USP, TRAACS® Magnesium Lysinate Glycinate Chelate) 133 mg
Zinc (as TRAACS®
Zinc Bisglycinate Chelate) 7.5 mg
Selenium (as Selenium
Glycinate Complex) 100 mcg
Copper (as TRAACS®
Copper Bisglycinate Chelate) 0.5 mg
Manganese (as TRAACS®
Manganese Bisglycinate Chelate) 2.5 mg
Chromium (as O-polynicotinate) 100 mcg
Molybdenum (as TRAACS®
Molybdenum Glycinate Chelate) 75 mcg
Strontium Citrate 0 g 
Boron (as Bororganic Glycine) 2.5 mg

Other Ingredients: Natural Vegetable Capsules, Microcrystalline Cellulose, Magnesium Stearate, and Silicon Dioxide
These tablets for bone density do not contain gluten, yeast, artificial colors, flavors, or preservatives.

Caution: Do not consume this product if you are pregnant or nursing. Consult your physician for further information.

Click here to view the Product Info Sheet

*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

References:

1. Braam, L. A., Knapen, M. H., et al. (2003). Vitamin K1 supplementation retards bone loss in postmenopausal women between 50 and 60 years of age. Calcified Tissue International, 73(1), 21-26. https://doi.org/10.1007/s00223-002-1012-2
2. Cauley, J. A., Lacroix, A. Z., Wu, L., Horwitz, M., et al. (2008). Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Annals of Internal Medicine, 149(4), 242-250. https://doi.org/10.7326/0003-4819-149-4-200808190-00006
3. Cianferotti, L., D’Asta, F., & Brandi, M. L. (2013). A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis. Therapeutic Advances in Musculoskeletal Disease, 5(3), 127-139. https://doi.org/10.1177/1759720X13487006
4. Connor, W. E. (2000). Importance of n-3 fatty acids in health and disease. American Journal of Clinical Nutrition, 71(1 Suppl), 171S-175S. https://doi.org/10.1093/ajcn/71.1.171S
5. Dyerberg, J., Madsen, P., Møller, J. M., Aardestrup, I., & Schmidt, E. B. (2010). Bioavailability of marine n-3 fatty acid formulations. Prostaglandins, Leukotrienes and Essential Fatty Acids, 83(3), 137-141. https://doi.org/10.1016/j.plefa.2010.06.001
6. Johnson, S. (2001). The multifaceted and widespread pathology of magnesium deficiency. Medical Hypotheses, 56(2), 163-170. https://doi.org/10.1016/S0306-9877(01)00010-9
7. Moshfegh, A., Goldman, J., Ahuja, J., Rhodes, D., & LaComb, R. (2009). What We Eat in America, NHANES 2005-2006: Usual nutrient intakes from food and water compared to 1997 dietary reference intakes for vitamin D, calcium, phosphorus, and magnesium. U.S. Department of Agriculture, Agricultural Research Service.
8. Nielson, F. H. (1988). Boron: An overlooked element of potential nutritional importance. Nutrition Today, 23(1), 4-7.
9. Nielsen, F. H. (1998). The justification for providing dietary guidance for the nutritional intake of boron. Biological Trace Element Research, 66(1-3), 319-330. https://doi.org/10.1007/BF02784838
10. Patrick, L. Y. (1999). Comparative absorption of calcium sources and calcium citrate malate prevention for osteoporosis. Alternative Medicine Review, 4(2), 74-85.
11. Stendig-Lindberg, G., Tepper, R., & Leichter, I. (1993). Trabecular bone density in a two-year controlled trial of peroral magnesium in osteoporosis. Magnesium Research, 6, 155-163.
12. Strause, L., Saltman, P., Smith, K. T., et al. (1994). Spinal bone loss in postmenopausal women supplemented with calcium and trace minerals. Journal of Nutrition, 124, 1060-1064. https://doi.org/10.1093/jn/124.6.1060
13. Weber, P. (1997). Management of osteoporosis: Is there a role for vitamin K? International Journal for Vitamin and Nutrition Research, 67(5), 350-356.
14. Wamberg, L., Pedersen, S. B., Richelsen, B., & Rejnmark, L. (2013). The effect of high-dose vitamin D supplementation on calciotropic hormones and bone mineral density in obese subjects with low levels of circulating 25-hydroxyvitamin D: Results from a randomized controlled study. Calcified Tissue International, 93(1), 69-77. https://doi.org/10.1007/s00223-013-9758-5
15. Bischoff-Ferrari, H. A., Giovannucci, E., Willett, W. C., et al. (2006). Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. American Journal of Clinical Nutrition, 84, 18-26. https://doi.org/10.1093/ajcn/84.1.18